Second-line antiretroviral therapy success rates and predictors among people living with HIV in Rwanda, 2019–2023
Jean Claude Kwizera, Clarisse Marie Claudine Simbi, Gallican Nshogoza Rwibasira, Bibiane Uwamahoro, Amanuel Kidane Andegiorgish · 2026
Read Second-line antiretroviral therapy success rates and predictors among people living with HIV in Rwanda, 2019–2023 by Jean Claude Kwizera, Clarisse Marie Claudine Simbi, Gallican Nshogoza Rwibasira, Bibiane Uwamahoro, Amanuel Kidane Andegiorgish (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13579886.txt.
Description
Jean Claude Kwizera and colleagues measure how well second line HIV therapy is working in Rwanda, in a 2026 study of records from 277 clinics. Patients who switch to backup drug mixes after a first regimen fails face a harder road to viral control. Files covered 726 people who started second line treatment between 2019 and 2023, most of them women and most on protease based mixes.
Viral suppression reached close to eighty nine percent, above the global average for second line care and better than the last national read, yet still short of the ninety five percent goal. Young people and students fared worst, as did patients with weak adherence, substance use, or other chronic disease. Living in the capital or in the north or south beat the east. Tailored youth care tops the fix list.
Catalog record
| CREATOR | Jean Claude Kwizera, Clarisse Marie Claudine Simbi, Gallican Nshogoza Rwibasira, Bibiane Uwamahoro, Amanuel Kidane Andegiorgish |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51278 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |